1-7 of 7
Michael C. Heinrich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy

Free
Thomas Mühlenberg, Julia Ketzer, Michael C. Heinrich, Susanne Grunewald, Adrian Marino-Enriquez, Marcel Trautmann, Wolfgang Hartmann, Eva Wardelmann, Jürgen Treckmann, Karl Worm, Stefanie Bertram, Thomas Herold, Hans-Ulrich Schildhaus, Hanno Glimm, Albrecht Stenzinger, Benedikt Brors, Peter Horak, Peter Hohenberger, Stefan Fröhling, Jonathan A. Fletcher, Sebastian Bauer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (11): 1985–1996.
https://doi.org/10.1158/1535-7163.MCT-18-1224
Published: 01 November 2019
View articletitled, KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy
Open the PDF for KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy in another window
Includes: Supplementary data
Journal Articles

Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity

Free
Alison C. Macleod, Lillian R. Klug, Janice Patterson, Diana J. Griffith, Carol Beadling, Ajia Town, Michael C. Heinrich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (12): 2840–2851.
https://doi.org/10.1158/1535-7163.MCT-13-0830
Published: 04 December 2014
View articletitled, Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity
Open the PDF for Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity in another window
Includes: Supplementary data
Journal Articles

Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors

Free
Michael C. Heinrich, Adrian Marino-Enriquez, Ajia Presnell, Rachel S. Donsky, Diana J. Griffith, Arin McKinley, Janice Patterson, Takahiro Taguchi, Cher-Wei Liang, Jonathan A. Fletcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1770–1780.
https://doi.org/10.1158/1535-7163.MCT-12-0223
Published: 08 August 2012
View articletitled, Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors
Open the PDF for Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors in another window
Journal Articles

The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

Free
Jenny E. Hernandez-Davies, Joan P. Zape, Elliot M. Landaw, Xiaolin Tan, Ajia Presnell, Diana Griffith, Michael C. Heinrich, Keith B. Glaser, Kathleen M. Sakamoto
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (6): 949–959.
https://doi.org/10.1158/1535-7163.MCT-10-0904
Published: 08 June 2011
View articletitled, The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Open the PDF for The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway in another window
Includes: Supplementary data
Journal Articles

Abstract B184: HSP90 inhibitor STA‐9090 potently suppresses heterogeneous KIT kinase‐domain mutations responsible for gastrointestinal stromal tumor progression during imatinib therapy

Free
Jonathan A. Fletcher, Maria Debiec‐Rychter, Stephen Swank, Jennifer Morgan, Bernadette Liegl, Tanya A. Rege, Michael C. Heinrich, Christopher C. Corless, Rachel Donsky, Christopher D.M. Fletcher, Chandrajit P. Raut, Wenbin Ou, Kevin Foley, Yuexiang Wang, George D. Demetri
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B184.
https://doi.org/10.1158/1535-7163.TARG-09-B184
Published: 10 December 2009
View articletitled, Abstract B184: HSP90 inhibitor STA‐9090 potently suppresses heterogeneous KIT kinase‐domain mutations responsible for gastrointestinal stromal tumor progression during imatinib therapy
Journal Articles

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

Free
Lori Rink, Yuliya Skorobogatko, Andrew V. Kossenkov, Martin G. Belinsky, Thomas Pajak, Michael C. Heinrich, Charles D. Blanke, Margaret von Mehren, Michael F. Ochs, Burton Eisenberg, Andrew K. Godwin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (8): 2172–2182.
https://doi.org/10.1158/1535-7163.MCT-09-0193
Published: 14 August 2009
View articletitled, Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
Open the PDF for Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor in another window
Journal Articles

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

Free
Marcus M. Schittenhelm, Christian Kollmannsberger, Karin Oechsle, Amy Harlow, Jason Morich, Friedemann Honecker, Raffael Kurek, Stephan Störkel, Lothar Kanz, Christopher L. Corless, Kwok-Kin Wong, Carsten Bokemeyer, Michael C. Heinrich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (3): 481–489.
https://doi.org/10.1158/1535-7163.MCT-08-1068
Published: 13 March 2009
View articletitled, Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Open the PDF for Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer in another window